[HTML][HTML] Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients
D de Miguel Pérez, A Rodriguez Martínez… - Scientific reports, 2020 - nature.com
Disseminated disease is present in≈ 50% of colorectal cancer patients upon diagnosis,
being responsible for most of cancer deaths. Addition of biological drugs, as Bevacizumab …
being responsible for most of cancer deaths. Addition of biological drugs, as Bevacizumab …
[HTML][HTML] Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients
D de Miguel Pérez, AR Martínez, AO Palomo… - Scientific …, 2020 - ncbi.nlm.nih.gov
Disseminated disease is present in≈ 50% of colorectal cancer patients upon diagnosis,
being responsible for most of cancer deaths. Addition of biological drugs, as Bevacizumab …
being responsible for most of cancer deaths. Addition of biological drugs, as Bevacizumab …
Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients
D de Miguel Pérez, A Rodriguez Martínez… - Scientific …, 2020 - ui.adsabs.harvard.edu
Disseminated disease is present in≈ 50% of colorectal cancer patients upon diagnosis,
being responsible for most of cancer deaths. Addition of biological drugs, as Bevacizumab …
being responsible for most of cancer deaths. Addition of biological drugs, as Bevacizumab …
Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients
D de Miguel Perez, A Rodriguez Martinez… - Scientific …, 2020 - docusalut.com
Disseminated disease is present in approximate to 50% of colorectal cancer patients upon
diagnosis, being responsible for most of cancer deaths. Addition of biological drugs, as …
diagnosis, being responsible for most of cancer deaths. Addition of biological drugs, as …
Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients
D Miguel-Pérez, A Rodríguez Martínez… - 2020 - digibug.ugr.es
Disseminated disease is present in≈ 50% of colorectal cancer patients upon diagnosis,
being responsible for most of cancer deaths. Addition of biological drugs, as Bevacizumab …
being responsible for most of cancer deaths. Addition of biological drugs, as Bevacizumab …
Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients.
D de Miguel Pérez, GP JL, LA JA, OS FG… - Scientific …, 2020 - europepmc.org
Disseminated disease is present in≈ 50% of colorectal cancer patients upon diagnosis,
being responsible for most of cancer deaths. Addition of biological drugs, as Bevacizumab …
being responsible for most of cancer deaths. Addition of biological drugs, as Bevacizumab …
[PDF][PDF] Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients
D de Miguel Pérez, AR Martínez, AO Palomo… - academia.edu
Results This study included 44 mCRC patients, 23 (52.3%) of them with primary tumours
located in the colon and 21 (47.7%) in the rectum. Median follow-up time for all patients was …
located in the colon and 21 (47.7%) in the rectum. Median follow-up time for all patients was …
Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients
D de Miguel Pérez, AR Martínez… - Scientific …, 2020 - pubmed.ncbi.nlm.nih.gov
Disseminated disease is present in≈ 50% of colorectal cancer patients upon diagnosis,
being responsible for most of cancer deaths. Addition of biological drugs, as Bevacizumab …
being responsible for most of cancer deaths. Addition of biological drugs, as Bevacizumab …
Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients.
D de Miguel Pérez, GP JL, LA JA, OS FG… - Scientific …, 2020 - europepmc.org
Disseminated disease is present in≈ 50% of colorectal cancer patients upon diagnosis,
being responsible for most of cancer deaths. Addition of biological drugs, as Bevacizumab …
being responsible for most of cancer deaths. Addition of biological drugs, as Bevacizumab …
[PDF][PDF] Extracellular vesicle-miRNAs as liquid biopsy biomarkers for disease identification and prognosis in metastatic colorectal cancer patients
D de Miguel Pérez, AR Martínez, AO Palomo… - academia.edu
Results This study included 44 mCRC patients, 23 (52.3%) of them with primary tumours
located in the colon and 21 (47.7%) in the rectum. Median follow-up time for all patients was …
located in the colon and 21 (47.7%) in the rectum. Median follow-up time for all patients was …